Holders over time
- TMO
- GILD
| Quarter | TMO | GILD |
|---|---|---|
| Q4 2020 | 33 holders, $39.2bn | 27 holders, $13.4bn |
| Q1 2021 | 35 holders, $36.5bn | 24 holders, $14.5bn |
| Q2 2021 | 33 holders, $38.3bn | 18 holders, $14.9bn |
| Q3 2021 | 32 holders, $42.6bn | 20 holders, $16.4bn |
| Q4 2021 | 38 holders, $50.1bn | 20 holders, $16.8bn |
| Q1 2022 | 32 holders, $43.2bn | 28 holders, $13.2bn |
| Q2 2022 | 33 holders, $38.9bn | 26 holders, $13.6bn |
| Q3 2022 | 26 holders, $34.3bn | 24 holders, $13.3bn |
| Q4 2022 | 29 holders, $37.0bn | 32 holders, $21.1bn |
| Q1 2023 | 35 holders, $37.1bn | 27 holders, $21.8bn |
| Q2 2023 | 39 holders, $33.5bn | 24 holders, $20.7bn |
| Q3 2023 | 39 holders, $32.6bn | 24 holders, $20.0bn |
| Q4 2023 | 41 holders, $32.7bn | 22 holders, $21.5bn |
| Q1 2024 | 30 holders, $34.1bn | 30 holders, $20.3bn |
| Q2 2024 | 38 holders, $30.6bn | 28 holders, $18.5bn |
| Q3 2024 | 30 holders, $33.8bn | 29 holders, $24.2bn |
| Q4 2024 | 36 holders, $27.6bn | 28 holders, $25.9bn |
| Q1 2025 | 31 holders, $24.2bn | 33 holders, $32.0bn |
| Q2 2025 | 39 holders, $18.8bn | 27 holders, $30.9bn |
| Q3 2025 | 32 holders, $21.9bn | 23 holders, $29.4bn |
| Q4 2025 | 32 holders, $29.9bn | 25 holders, $34.3bn |
| Q1 2026 | 34 holders, $24.4bn | 25 holders, $38.5bn |
| Q2 2026 | 36 holders, $26.4bn | 26 holders, $34.2bn |
| Q3 2026 | 35 holders, $40.3bn | 17 holders, $31.5bn |
Thermo Fisher Scientific Inc
- Holders
- 35
- Reported value
- $40.3bn
- Buyers
- 20
- Sellers
- 30
Breadth -10 among 89 comparable managers.
Gilead Sciences Inc
- Holders
- 17
- Reported value
- $31.5bn
- Buyers
- 18
- Sellers
- 21
Breadth -3 among 89 comparable managers.
Who holds both, Q3 2026
Both (11)
Arrowstreet Capital LP, Capital Research Global Investors, Capital World Investors, Dodge & Cox, Fidelity (FMR LLC), Invesco Ltd, MFS Investment Management, Neuberger Berman Group LLC, Walleye Capital LLC, Wellington Management Group LLP, Woodline Partners LP
Only TMO (24)
AllianceBernstein LP, AQR Capital Management LLC, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Caxton Associates LLP, D. E. Shaw & Co., D1 Capital Partners LP, Egerton Capital UK LLP, Farallon Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Glenview Capital Management LLC, Holocene Advisors LP, Lone Pine Capital LLC, Man Group PLC, Markel Group Inc, Maverick Capital Ltd, Point72 Asset Management LP, T. Rowe Price Associates Inc, Verition Fund Management LLC, Viking Global Investors LP, Winton Group Ltd
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.